目的：主要探究银杏达莫以及前列地尔对椎-基底动脉供血不足眩晕症（vertebrobasilarin sufficient vertigo,VBIV）患者的影响。方法：选取2019年5月—2023年4月收治的150例VBIV患者,通过单双号法分为对照组和观察组,每组各75例。对照组采用前列地尔（alprostadil,PGE1）进行治疗,观察组给予PGE1联合银杏达莫治疗。比较治疗2周后两组患者的临床疗效;比较治疗前及治疗2周后两组患者血流动力学[左椎动脉流速（left vertebral artery,LVA）、右椎动脉流速（right vertebral artery,RVA）、基底动脉流速（basilar artery,BA）]、血液流变学[红细胞沉降率（erythrocyte sedimentation rate,ESR）、红细胞压积（hematocrit,HCT）、全血高切黏度（high-shear viscosity,HSV）、全血低切黏度（low-shear viscosity,LSV）]、氧化应激指标水平[超氧化物歧化酶（superoxide dismutase,SOD）、一氧化氮（nitric oxide,NO）、丙二醛（malondialdehyde,MDA）、谷胱甘肽过氧化物酶（glutathione peroxidase,GSH-Px）]、炎症因子水平[超敏C反应蛋白（hypersensitive C-reactive protein,hs-CRP）、白细胞介素-6（interleukin-6,IL-6）]、眩晕程度[视觉性眩晕量表（visual vertigo analogue scale,VVAS）、眩晕障碍量表（dizziness handicap inventory,DHI）]差异;记录治疗期间的用药安全性。结果：治疗2周后,观察组疗效总有效率高于对照组;治疗2周后,两组患者LVA、RVA、BA、SOD、NO、GSH-Px较治疗前升高,观察组高于对照组;治疗2周后,两组患者ESR、HCT、HSV、LSV、MDA、hs-CRP、IL-6降低,观察组低于对照组;治疗2周后,两组患者VVAS、DHI评分较治疗前显著下降,观察组低于对照组;治疗期间,两组患者不良反应发生率无显著差异。结论：银杏达莫注射液联合前列地尔治疗VBIV患者效果显著,能有效恢复患者血流动力学、血液流变学,减轻炎症反应和氧化应激反应,有助于改善其眩晕症状,具有较高安全性。

Objective To mainly explore the influence of ginkgo leaf extract dipyridamole injection and alprostadil on patients with vertebrobasilar insufficiency vertigo (VBIV). Methods 150 patients with VBIV were selected from May 2019 to April 2023, and they were divided into control group and observation group by the odd-even number method, with 75 cases in each group. Control group was treated with alprostadil (PGE1), and observation group was given PGE1 combined with ginkgo leaf extract dipyridamole. The clinical efficacy after 2 weeks of treatment, hemodynamics [left vertebral artery (LVA) flow velocity, right vertebral artery (RVA) flow velocity, basal artery flow velocity (BA) ], hemorheology [erythrocyte sedimentation rate (ESR), hematocrit (HCT), whole blood high-shear viscosity (HSV), whole blood low-shear viscosity (LSV) ], oxidative stress indicators [serum superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), glutathione peroxidase (GSH-Px) ], inflammatory factors [hypersensitive C-reactive protein (hs-CRP), interleukin-6(IL-6) ] and vertigo degree[Visual Vertigo Analogue Scale (VVAS), dizziness handicap inventory (DHI) ] before treatment and after 2 weeks of treatment and drug safety during treatment were compared between both groups. Results After 2 weeks of treatment, the total effective rate of efficacy in observation group was significantly higher compared with that in control group. The LVA, RVA, BA, SOD, NO and GSH-Px in both groups after 2 weeks of treatment were enhanced compared with those before treatment, and the indicators were higher in observation group. The ESR, HCT, HSV, LSV, MDA, hs-CRP and IL-6 were reduced after 2 weeks of treatment in the two groups, and the indicators in observation group were lower in comparison with control group. After 2 weeks of treatment, the scores of VVAS and DHI in both groups were significantly decreased compared with those before treatment, and the scores in observation group were lower compared to control group. During treatment, the differences were not significant in the incidence rates of adverse reactions between the two groups. Conclusion Ginkgo leaf extract dipyridamole injection combined with alprostadil has a significant effect in treating VBIV, and it can effectively restore the hemodynamics and hemorheology, relieve the inflammatory response and oxidative stress response, and help improve vertigo symptoms, with high safety.